meta|evidence COVID-19
  • Living systematic review and meta-analysis
  • ***** adjuvant therapies
  • ***** anti-inflammatoty and immuno-therapy
  • ***** antiandrogenic
  • ***** antiviral and associated therapy
  • ***** control
  • ***** Drugs for acid related disorders
  • ***** miscellaneous
  • ***** Oral antidiabetic drugs
  • ***** Renin-angiotensin-system-acting agents
  • vaccines
  • A EFFACER BBV152 (Bharat Biotech, India)
  • A EFFACER Janssen Ad.26.COV2.S vaccine (JNJ-78436725)
  • A EFFACER_ Vero cell
  • A EFFACER_sequential Immunization
  • BCG vaccination
  • complete primary vaccine series
  • CoVLP (MT-2766, Medicago)
  • DNA vaccine
  • ebola vaccine
  • first booster dose
  • heterologous prime-boost
  • Inactivated virus vaccine
  • mRNA vaccine
  • Non replicating viral vector
  • protein subunit vaccine
  • Anhui Zhifei Longcom
  • CoVax-19 SpikoGen
  • Nuvaxovid (NVX-CoV2373) Novavax
  • Sanofi/GSK recombinant protein vaccine
  • SCB-2019
  • Replicating Viral Vector
  • seasonal influenza vaccines
  • second booster dose
  • virus-like particles vaccine
  • ***** Vitamins
  • COVID 19 hospitalized
  • COVID 19 all comers
  • COVID-19 mild to moderate
  • COVID-19 severe or critically
  • COVID 19 outpatients
  • COVID-19 (hospitalized or not)
  • COVID-19 prophylaxis (children)
  • COVID-19 prophylaxis (excluding children)
  • infections other than COVID-19
  • Long COVID-19
  • preventing respiratory virus transmission
  • secondary prevention